PE20091030A1 - Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa - Google Patents

Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa

Info

Publication number
PE20091030A1
PE20091030A1 PE2008001680A PE2008001680A PE20091030A1 PE 20091030 A1 PE20091030 A1 PE 20091030A1 PE 2008001680 A PE2008001680 A PE 2008001680A PE 2008001680 A PE2008001680 A PE 2008001680A PE 20091030 A1 PE20091030 A1 PE 20091030A1
Authority
PE
Peru
Prior art keywords
agent
combination
pharmaceutical compositions
steroid anti
compositions including
Prior art date
Application number
PE2008001680A
Other languages
English (en)
Inventor
Armenta Maria Elena Garcia
Murillo Josefina Santos
Ochoa Victor Guillermo Alvarez
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of PE20091030A1 publication Critical patent/PE20091030A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN AGENTE ANTIINFLAMATORIO NO ESTEROIDEO TAL COMO MELOXICAM EN UNA CONCENTRACION DE 7.5 MG A 45.0 MG O CELECOXIB EN UNA CONCENTRACION DE 100.0 MG A 600.0 MG, Y UN AGENTE INHIBIDOR DE LA ENZIMA XANTINO OXIDASA TAL COMO ALOPURINOL EN UNA CONCENTRACION DE 100.0 MG A 800.0 MG. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA GOTA, ARTRITIS GOTOSA Y ENFERMEDADES RELACIONADAS
PE2008001680A 2007-09-26 2008-09-26 Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa PE20091030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007011927A MX2007011927A (es) 2007-09-26 2007-09-26 Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.

Publications (1)

Publication Number Publication Date
PE20091030A1 true PE20091030A1 (es) 2009-08-06

Family

ID=40511631

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001680A PE20091030A1 (es) 2007-09-26 2008-09-26 Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa

Country Status (10)

Country Link
EP (1) EP2210604A4 (es)
AR (1) AR068560A1 (es)
BR (1) BRPI0817563A2 (es)
CL (1) CL2008002884A1 (es)
CO (1) CO6270220A2 (es)
EC (1) ECSP10010054A (es)
MX (1) MX2007011927A (es)
PE (1) PE20091030A1 (es)
UY (1) UY31363A1 (es)
WO (1) WO2009041798A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS

Also Published As

Publication number Publication date
MX2007011927A (es) 2009-03-26
WO2009041798A1 (es) 2009-04-02
CL2008002884A1 (es) 2009-03-20
AR068560A1 (es) 2009-11-18
WO2009041798A8 (es) 2010-05-14
CO6270220A2 (es) 2011-04-20
EP2210604A1 (en) 2010-07-28
BRPI0817563A2 (pt) 2015-03-31
ECSP10010054A (es) 2010-04-30
EP2210604A4 (en) 2010-12-29
UY31363A1 (es) 2009-03-31

Similar Documents

Publication Publication Date Title
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
MX2010001823A (es) Piperidinil- y piperazinil-sulfonamidas biciclicas sustituidas utiles para inhibir 11beta-hidroxiesteroide deshidrogenasa tipo-1.
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
BR112013020456A2 (pt) nova composição antifúngica
PE20091030A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
MX2010001822A (es) Azepina- y diazepina-sulfonamidas sustituidas utiles para inhibir 11beta-hidroxiesteroide deshidrogenasa tipo-1.
PE20071004A1 (es) Composiciones farmaceuticas que comprenden la combinacion de ivabradina y perindropil
ATE474574T1 (de) Imidazoazephinonverbindungen
MX2020003660A (es) Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
AR062613A1 (es) Formulacion de compuestos organicos
GT200900316A (es) Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal
PE20090725A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiartritico y un agente inhibidor de la interleucina-1, util para el control y tratamiento de la osteoartrosis y enfermedades relacionadas

Legal Events

Date Code Title Description
FD Application declared void or lapsed